Efficacy, Safety and Cost of Regorafenib in Patients with Metastatic Colorectal Cancer in French Clinical Practice

BACKGROUND: Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Clin Med Insights Oncol
Main Authors: Calcagno, Fabien, Lenoble, Sabrina, Lakkis, Zaher, Nguyen, Thierry, Limat, Samuel, Borg, Christophe, Jary, Marine, Kim, Stefano, Nerich, Virginie
Format: Artigo
Jezik:Inglês
Izdano: Libertas Academica 2016
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4933532/
https://ncbi.nlm.nih.gov/pubmed/27398042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4137/CMO.S38335
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki